Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 3,086 matching trials from the live ClinicalTrials.gov search.
Conditions
Solid Tumor, Adult
Interventions
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 13 more
Conditions
Advanced Solid Tumors
Interventions
TGW101
Drug
Lead sponsor
Tagworks Pharmaceuticals BV
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Philadelphia, Pennsylvania + 4 more
Conditions
Advanced Solid Tumors, Lymphoma
Interventions
TAK-901
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Rockledge, Pennsylvania
Conditions
Multiple Myeloma, Advanced Solid Tumors
Interventions
Ixazomib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Atlanta, Georgia • Peoria, Illinois • Fairway, Kansas + 7 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, irinotecan hydrochloride, semaxanib
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Cancer
Interventions
Birinapant
Drug
Lead sponsor
TetraLogic Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Fort Lauderdale, Florida • Detroit, Michigan • Buffalo, New York + 3 more
Conditions
Neoplasm Malignant
Interventions
Cabazitaxel (XRP6258)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
La Jolla, California • Loma Linda, California • Washington D.C., District of Columbia + 11 more
Conditions
Advanced Solid Tumors, Colorectal Cancer (CRC), Non-Small Cell Lung Cancer, Uterine Cancer, KRAS G12C Mutations, KRAS G12S Mutations
Interventions
KQB368
Drug
Lead sponsor
Kumquat Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
14
States / cities
Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 11 more
Conditions
Solid Tumors, Lymphomas
Interventions
FF-10502-01
Drug
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Denver, Colorado • Houston, Texas
Conditions
Hepatoma, Advanced Solid Tumor
Interventions
irinotecan and ON 01910.Na, oxaliplatin and ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Tumors, Lymphoma, Multiple Myeloma
Interventions
ridaforolimus
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
1-methyl-d-tryptophan, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Tampa, Florida • Richmond, Virginia
Conditions
Advanced Solid Tumor, Ovarian Cancer
Interventions
Neratinib 160 mg, Neratinib 200 mg, Neratinib 240 mg, Niraparib 100 mg, Niraparib 200 mg, Niraparib 300 mg, Niraparib at RP2D, Neratinib at RP2D
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma
Interventions
PRT7732
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
San Francisco, California • Detroit, Michigan • New York, New York + 7 more
Conditions
Advanced Solid Tumors
Interventions
Amrubicin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
La Jolla, California • Santa Monica, California • Indianapolis, Indiana + 5 more
Conditions
Advanced Tumors
Interventions
CPI-300
Drug
Lead sponsor
Coordination Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Scottsdale, Arizona • Lake Mary, Florida • Cleveland, Ohio + 1 more
Conditions
Advanced Solid Tumours
Interventions
Adavosertib, Itraconazole, Rifampicin, Omeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Portland, Oregon • Austin, Texas • Dallas, Texas
Conditions
Tumor
Interventions
belinostat, 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, triapine
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Tucson, Arizona • New Haven, Connecticut
Conditions
Advanced Cancer
Interventions
BMS-986249, Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
19
States / cities
Aurora, Colorado • Denver, Colorado • Miami, Florida + 15 more
Conditions
Solid Tumor
Interventions
23ME-01473
Drug
Lead sponsor
23andMe, Inc.
Industry
Eligibility
18 Years to 110 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Grand Rapids, Michigan • Portland, Oregon • San Antonio, Texas
Conditions
Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Esophagus Cancer, Liver Cancer, Ovary Cancer, Advanced or Metastatic Treatment-refractory Solid Tumor Malignancies
Interventions
NP-G2-044
Drug
Lead sponsor
Novita Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • New York, New York
Conditions
Solid Tumor
Interventions
SAR445877, Cetuximab, ADG126, Bevacizumab, Nivolumab, Ipilimumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
9
States / cities
Newark, Delaware • Iowa City, Iowa • Westwood, Kansas + 6 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Sorafenib
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Sacramento, California